| Literature DB >> 33680371 |
Ebrahim Karimi1, Fatemeh Ghalibafan2, Akram Esfandani3, Niusha Manoochehri Arash4, Sassan Mohammadi4, Azad Khaledi5, Hakimeh Akbari6, Maria Khurshid4.
Abstract
BACKGROUND: The purpose of this study was to systematically review the prevalence of class 1 integrons, antibiotic resistance pattern in Pseudomonas aeruginosa (P. aeruginosa) isolated from clinical samples other than burn samples.Entities:
Keywords: Burns; Drug resistance; Integrons; Pseudomonas aeruginosa
Year: 2021 PMID: 33680371 PMCID: PMC7903437 DOI: 10.18502/ajmb.v13i1.4575
Source DB: PubMed Journal: Avicenna J Med Biotechnol ISSN: 2008-2835
Supplementary figure.Flow chart diagram of selection studies.
Figure 1.Forest plot of the meta-analysis of epidemiology of class 1 integron in P. aeruginosa isolated from clinical specimens.
Characteristics of selected studies from Iranian patients
| 2013 | Babol | 54 | 53 (98.1) | 20 (37) | ICU | Yes | |
| 2016 | Bandar Abbas | 90 | 12(13.3) | 12(13.3) | ICU, non-ICU | yes | |
| 2017 | Gonabad | 95 | - | 29 (30.5) | Different wards | - | |
| 2018 | Tabriz | 200 | 106(53) | 55 (27.5) | Different wards | Yes | |
| 2018 | Isfahan | 72 | - | 40(55.6) | ICU, non-ICU | Yes | |
| 2018 | Tabriz | 57 | 57(100) | 57(99.1) | ICU | Yes | |
| 2018 | Different | 143 | 12(8.4) | 27(18.9) | CF Patient (Iran) | - | |
| 2018 | Tehran | 21 | 21(100) | 19(90.5) | Different wards | Yes |
Correlation between Int1 and antibiotic resistance, ICU: Intensive care unit, CF: Cystic fibrosis.
Analysis of epidemiology of class 1 integron, and MDRs in P. aeruginosa isolated from clinical specimens
| 8 | 40(26.1–55.8) | 1.2 | 0.00 | 74.1 | 0.00 | 90.5 | 1.8 | 0.12 | |
| 6 | 70.1(32.6–91.9) | 1 | 0.00 | 119.1 | 0.00 | 95.8 | 0.43 | 0.68 | |
Note: Int1: Class 1 integron; MDR: Multi-drug resistant.
Figure 2.Funnel plot of meta-analysis on the epidemiology of class 1 integron in P. aeruginosa isolated from clinical samples.
Figure 3.Antibiotic resistance patterns in P. aeruginosa isolated from clinical samples. Imipenem (IPM), Ciprofloxacin (CIP), Gentamicin (GM), Amikacin (AK), Ceftriaxone (CRO), Ceftazidime (CAZ), Cefepime (FEP), Piperacillin/tazobactam (TBZ), Aztreonam (ATM), Cloxacillin (CX), Tobramycin (TOB), Ticarcillin (TIC), Carbenicillin (PY), Cefotaxime (CTX), Norfloxacin (NOR), Polymyxin B (PB), Colistin (CT).
Subgroups analysis for antibiotic resistance in P. aeruginosa isolated from clinical samples other than burn samples
| 7 | 47.5(32.8–62.7) | 0.31 | 0.00 | 352.6 | 0.42 | 96.3 | 0.83 | 0.75 | |
| 8 | 62.4(48.6–74.5) | 1.7 | 0.00 | 406.7 | 0.2 | 96.06 | 1.1 | 0.07 | |
| 7 | 60.5(47.4–72.2) | 1.5 | 0.11 | 288.9 | 0.37 | 95.1 | 0.9 | 0.11 | |
| 8 | 57.4(46.4–67.8) | 1.3 | 0.00 | 262.2 | 0.9 | 94.2 | 0.1 | 0.18 | |
| 5 | 58.6(29.8–82.5) | 0.56 | 0.00 | 129.8 | 0.72 | 96.9 | 0.37 | 0.57 | |
| 6 | 57.8(44.4–70.2) | 1.14 | 0.00 | 289.6 | 0.99 | 95.5 | 0.00 | 0.25 | |
| 5 | 46.4(26.6–67.4) | 0.32 | 0.00 | 250.9 | 0.34 | 96.8 | 1 | 0.74 | |
| 6 | 50.6(40.4–60.8) | 0.11 | 0.00 | 102.9 | 0.35 | 91.2 | 0.97 | 0.9 | |
| 5 | 48.1(27.9–68.9) | 0.17 | 0.00 | 180.7 | 0.1 | 96.6 | 1.9 | 0.86 | |
| 3 | 77.4(62.8–87.4) | 3.4 | 0.00 | 32.8 | 0.23 | 90.8 | 1.6 | 0.001 | |
| 6 | 65.8(51.2–77.9) | 2.1 | 0.00 | 160.8 | 0.78 | 95 | 0.28 | 0.035 | |
| 8 | 55.4(40.1–69.7) | 0.68 | 0.00 | 102.5 | 0.70 | 93.1 | 0.39 | 0.49 | |
| 3 | 79.9(72.7–85.6) | 6.7 | 0.00 | 2.7 | 0.80 | 28.3 | 0.32 | 0.00 | |
| 3 | 76.6(72.1–80.6) | 9.7 | 0.00 | 9.6 | 0.96 | 79.3 | 0.05 | 0.00 | |
| 4 | 57.3(11.5–93.3) | 0.24 | 0.00 | 180.9 | 0.45 | 98.3 | 0.91 | 0.81 | |
| 3 | 1(1–2.5) | 6.4 | 0.00 | 0.001 | 0.05 | 0.00 | 121 | 0.00 | |
| 3 | 1(1–1.25) | 4.1 | 0.00 | 0.001 | 0.06 | 0.00 | 102 | 0.00 | |
Note: Cl: Confidence interval, Q: Cochran's Q test, P: p value, T: t student test, I2: I-square, Z: Z-value.